Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and. | August 11, 2022
On July 7, 2022, invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) commenced a cash tender offer for all of the issued and
Proposed ~US$161 million all-cash acquisition to accelerate invoX's strategy to build Sino Biopharm's International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwideThe